Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurodevelopmental Disorder Clear all

Conditions: ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions: CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more

Conditions: Autism Spectrum Disorder, Quality of Life, Sleep, Anxiety
Interventions: Reconnect, Coconut oil Comparator; Biological
Lead sponsor: Jill Hollway; Other
Eligibility: 3 Years to 9 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Autism
Interventions: Propranolol, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 3 Years to 10 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Autism Spectrum Disorder, Mental Disorders
Interventions: Therapeutic Horseback Riding, Barn Activity, Hybrid; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 17 Years
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Portland, Maine

Conditions: Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
Interventions: Groundskeeper; Device
Lead sponsor: CogCubed, Corp; Industry
Eligibility: 5 Years to 12 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Dothan, Alabama • Phoenix, Arizona • San Francisco, California + 24 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions: Centanafadine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more

Conditions: Reading Disability
Interventions: Sham intervention, RLN real non-invasive brain stimulation intervention, RLN and CCN real non-invasive brain stimulation intervention; Device
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autism, Sleep Disturbances in Children, Sleep
Interventions: Power Down bedtime manipulation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autism Spectrum Disorder
Interventions: Ballet for All Kids; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 7 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Encopresis, Autism Spectrum Disorder
Interventions: MIE Treatment, Glycerin Suppository, Treatment as Usual (TAU); Behavioral · Drug · Combination Product
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autism Spectrum Disorders
Interventions: emotion regulation training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Tourette Syndrome, Tic Disorders
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Traumatic Brain Injury, TBI, ADHD
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AKL-T01; Device
Lead sponsor: Akili Interactive Labs, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Maitland, Florida + 10 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more

Conditions: Autism Spectrum Disorder
Interventions: hCT-MSC infusion; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Months to 48 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tourette's Disorder, Tic Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 7 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Dothan, Alabama • Goodyear, Arizona • Orange, California + 23 more

Conditions: Rett Syndrome
Interventions: NGN-401; Genetic
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 3 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more

Conditions: Development Delay, Social Skills, Parents
Interventions: Parent Training, Video Modeling; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 3 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: TC-5619-238 5mg, TC-5619-238 25mg, Placebo; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more

Conditions: Autism, Autism Spectrum Disorder
Interventions: Reciprocal Imitation Training, music-enhanced Reciprocal Imitation Training; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Months to 36 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Multi-Setting Early Intervention, Community Intervention; Behavioral
Lead sponsor: Lehigh University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Search by objective public record fields.

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

Essential Oils for Enhancing QOL in ASD

Combined Effects of Early Behavioral Intervention and Propranolol on ASD

Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth

GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

Noninvasive Brain Stimulation to Enhance Reading Comprehension Ability in Adults

Differences in Rest, Emotion, and Arousal Modulation in Youth

Approach to Dance for Autism

Treatment of Encopresis in Children With Autism Spectrum Disorders

Parents Workgroup About Emotion Regulation

Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder

Methylphenidate for Attention Problems After Pediatric TBI

Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Home-Based Social Skills Intervention for Young Children With Developmental Delays

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers

Preventing Behavior Problems in Children With ADHD